LAUSR

About LAUSR
Donate
Contact Us

Follow us:

You are not signed in:

Sign Up!


   Articles with "brafi" as a keyword



Photo by nci from unsplash

Targeting the hedgehog transcription factors GLI1 and GLI2 restores sensitivity to vemurafenib-resistant human melanoma cells

Sign Up to like & get
recommendations! Published in 2017 at "Oncogene"

DOI: 10.1038/onc.2016.348

Abstract: BRAF inhibitor (BRAFi) therapy for melanoma patients harboring the V600E mutation is initially highly effective, but almost all patients relapse within a few months. Understanding the molecular mechanisms underpinning BRAFi-based therapy is therefore an important… read more here.

Keywords: melanoma; gli1 gli2; brafi; vemurafenib resistant ... See more keywords
Photo by onthesearchforpineapples from unsplash

A patent review of BRAF inhibitors: 2013-2018

Sign Up to like & get
recommendations! Published in 2019 at "Expert Opinion on Therapeutic Patents"

DOI: 10.1080/13543776.2019.1640680

Abstract: ABSTRACT Introduction: As a key element in arguably the most important pathway MAPK signaling, the BRAF kinase gives rise to severe diseases including cancers when pathologically activated. Extensive research on BRAFi (BRAF inhibitor) has been… read more here.

Keywords: brafi; trial registration; registration clinicaltrials; braf ... See more keywords
Photo by anniespratt from unsplash

BRAFi‐associated panniculitis – an emerging side effect with a variable histological picture: report of two cases and review of the literature

Sign Up to like & get
recommendations! Published in 2017 at "Journal of Cutaneous Pathology"

DOI: 10.1111/cup.12857

Abstract: To the Editor , BRAF inhibitors (BRAFi) vemurafenib and dabrafenib have become the standard of care of metastatic melanoma. Well-described cutaneous side effects include secondary tumors such as squamous cell carcinomas and secondary melanomas and… read more here.

Keywords: literature; brafi; panniculitis emerging; brafi associated ... See more keywords
Photo by refargotohp from unsplash

7 Evolution of cross-resistance to CD8+ T cells in the course of BRAF and MEK inhibitor treatment in BRAFV600E melanoma

Sign Up to like & get
recommendations! Published in 2018 at "ESMO Open"

DOI: 10.1136/esmoopen-2018-eacr25.7

Abstract: Introduction The BRAFV600 mutation, expressed in approximately 50% of melanomas, mediates constitutive activation of the BRAF-MEK-ERK in the MAPK signalling pathway and therefore tumour proliferation. Rapid and high rate of clinical responses can be achieved… read more here.

Keywords: melanoma; evolution; brafi; treatment ... See more keywords
Photo by nci from unsplash

BRAF V600E mutation and BRAF kinase inhibitors in conjunction with stereotactic radiosurgery for intracranial melanoma metastases.

Sign Up to like & get
recommendations! Published in 2017 at "Journal of neurosurgery"

DOI: 10.3171/2016.2.jns1633

Abstract: OBJECTIVE Recent advancements in molecular biology have identified the BRAF mutation as a common mutation in melanoma. The wide use of BRAF kinase inhibitor ( BRAFi) in patients with metastatic melanoma has been established. The… read more here.

Keywords: melanoma; brafi; braf; group ... See more keywords
Photo by nci from unsplash

Increased MARCKS Activity in BRAF Inhibitor-Resistant Melanoma Cells Is Essential for Their Enhanced Metastatic Behavior Independent of Elevated WNT5A and IL-6 Signaling

Sign Up to like & get
recommendations! Published in 2022 at "Cancers"

DOI: 10.3390/cancers14246077

Abstract: Simple Summary Approximately 60% of all melanoma patients have cancer with an activating BRAF mutation that can be effectively treated with a BRAF inhibitor. Unfortunately, such treatment often leads to rapid development of BRAF inhibitor-resistance.… read more here.

Keywords: melanoma; brafi; melanoma cells; activity ... See more keywords
Photo by andreacaramello from unsplash

NECTIN4: A Novel Therapeutic Target for Melanoma

Sign Up to like & get
recommendations! Published in 2021 at "International Journal of Molecular Sciences"

DOI: 10.3390/ijms22020976

Abstract: Malignant melanoma is the most common lethal skin cancer and causes death in a short time when metastasized. Although BRAF inhibitors (BRAFi) have greatly improved the prognosis of BRAF-mutated melanoma, drug resistance is a major… read more here.

Keywords: melanoma; nectin4 novel; brafi; brafi resistant ... See more keywords
Photo by finnnyc from unsplash

Melanoma: BRAFi Rechallenge

Sign Up to like & get
recommendations! Published in 2023 at "Medicina"

DOI: 10.3390/medicina59050975

Abstract: Melanoma is the most aggressive type of skin cancer. Half of melanoma cases are characterized by the mutation BRAF V600. The case presented concerns a 41-year-old patient with locally advanced melanoma, being positive in mutation… read more here.

Keywords: brafi rechallenge; brafi; targeted therapy; melanoma ... See more keywords